Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 29;24(1):770.
doi: 10.1186/s12891-023-06865-1.

Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study

Simon Bishop  1 , Melanie Jay Narayanasamy  2 , Zoe Paskins  3   4 , Nadia Corp  5 , Anastasios Bastounis  6 , Jill Griffin  7 , Neil Gittoes  8 , Jo Leonardi-Bee  9 , Tessa Langley  9 , Opinder Sahota  10
Affiliations

Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study

Simon Bishop et al. BMC Musculoskelet Disord. .

Abstract

Background: Bisphosphonate medications, including alendronate, ibandronate and risedronate administered orally and zoledronate, administered intravenously, are commonly prescribed for the treatment of osteoporosis based on evidence that, correctly taken, bisphosphonates can improve bone strength and lead to a reduction in the risk of fragility fractures. However, it is currently unclear how decisions to select between bisphosphonate regimens, including intravenous regimen, are made in practice and how clinicians support patients with different treatments.

Methods: This was an interpretivist qualitative study. 23 semi-structured telephone interviews were conducted with a sample of general practitioners (GPs), secondary care clinicians, specialist experts as well as those providing and leading novel treatments including participants from a community intravenous (IV) zoledronate service. Data analysis was undertaken through a process of iterative categorisation.

Results: The results report clinicians varying experiences of making treatment choices, as well as wider aspects of osteoporosis care. Secondary care and specialist clinicians conveyed some confidence in making treatment choices including on selecting IV treatment. This was aided by access to diagnostic testing and medication expertise. In contrast GPs reported a number of challenges in prescribing bisphosphonate medications for osteoporosis and uncertainty about treatment choice. Results also highlight how administering IV zoledronate was seen as an opportunity to engage in broader care practices.

Conclusion: Approaches to making treatment decisions and supporting patients when prescribing bisphosphonates for osteoporosis vary in practice. This study points to the need to co-ordinate osteoporosis treatment and care across different care providers.

Keywords: Adherence; Bisphosphonate regimens; Qualitative research; Treatment choice; Zoledronate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ. 2015;351:h3783. doi: 10.1136/bmj.h3783. - DOI - PubMed
    1. Byun JH, Jang S, Lee S, Park S, Yoon HK, Yoon BH, Ha YC. The Efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis. J Bone Metab. 2017;24(1):37–49. doi: 10.11005/jbm.2017.24.1.37. - DOI - PMC - PubMed
    1. Bastounis A, Langley T, Davis S, Paskins Z, Gittoes N, Leonardi-Bee J, Sahota O. Assessing the effectiveness of bisphosphonates for the prevention of fragility fractures: an updated systematic review and network meta-analyses. JBMR Plus. 2022;6(5):e10620. doi: 10.1002/jbm4.10620. - DOI - PMC - PubMed
    1. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14(4):571–581. doi: 10.1016/j.jval.2010.11.010. - DOI - PubMed
    1. Shalev V, Sharman Moser S, Goldshtein I, Yu J, Well C, Ish-Shalom., S., Rouach, V., Chodick, G. Adherence with bisphosphonates and long-term risk of hip fractures: a nested case-control study using real-world data. Ann Pharmacother. 2017;51(9):757–767. doi: 10.1177/1060028017710482. - DOI - PubMed

MeSH terms